An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Latest Information Update: 30 Oct 2023
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 24 Oct 2023 Status changed from active, no longer recruiting to completed.
- 07 Jan 2019 Planned primary completion date changed from 30 Oct 2018 to 4 Oct 2023.
- 16 Oct 2017 Planned End Date changed from 30 Oct 2018 to 4 Oct 2023.